$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

$strm Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223021263 Filed on June 14, 2023

Income Statement

Concept	2023 Q2	2022 Q2
Revenue	$5.332M	$5.935M
YoY Change	-10.16%	101.12%
Cost Of Revenue	$2.786M	$3.209M
YoY Change	-13.18%	123.31%
Gross Profit	$2.546M	$2.726M
YoY Change	-6.6%	80.05%
Gross Profit Margin	47.75%	45.93%
Selling, General & Admin	$3.806M	$4.501M
YoY Change	-15.44%	76.44%
% of Gross Profit	149.49%	165.11%
Research & Development	$1.701M	$1.310K
YoY Change	129747.33%	-99.87%
% of Gross Profit	66.81%	0.05%
Depreciation & Amortization	$1.059M	$971.0K
YoY Change	9.06%	51.25%
% of Gross Profit	41.59%	35.62%
Operating Expenses	$5.507M	$5.813M
YoY Change	-5.26%	64.77%
Operating Profit	-$2.996M	-$3.087M
YoY Change	-2.95%	53.28%
Interest Expense	$248.0K	-$132.0K
YoY Change	-287.88%	915.38%
% of Operating Profit
Other Income/Expense, Net	$32.00K	$533.0K
YoY Change	-94.0%	3453.33%
Pretax Income	-$2.848M	-$2.776M
YoY Change	2.59%	13.17%
Income Tax	$53.00K	$11.00K
% Of Pretax Income
Net Earnings	-$2.901M	-$2.787M
YoY Change	4.09%	30.11%
Net Earnings / Revenue	-54.41%	-46.96%
Basic Earnings Per Share	-$0.05	-$0.06
Diluted Earnings Per Share	-$0.05	-$59.26K
COMMON SHARES
Basic Shares Outstanding	58.61M shares	47.03M shares
Diluted Shares Outstanding	55.97M shares	47.03M shares

Balance Sheet

Concept	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.987M	$7.955M
YoY Change	-24.74%	-52.44%
Cash & Equivalents	$5.987M	$7.955M
Short-Term Investments
Other Short-Term Assets	$717.0K	$423.0K
YoY Change	69.5%	-70.65%
Inventory
Prepaid Expenses
Receivables	$4.280M	$4.660M
Other Receivables	$535.0K	$671.0K
Total Short-Term Assets	$11.52M	$13.71M
YoY Change	-15.97%	-36.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$99.00K	$282.0K
YoY Change	-64.89%	-34.72%
Goodwill	$23.09M
YoY Change
Intangibles	$14.34M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.598M	$1.002M
YoY Change	59.48%	4.59%
Total Long-Term Assets	$44.97M	$46.25M
YoY Change	-2.78%	150.98%
TOTAL ASSETS
Total Short-Term Assets	$11.52M	$13.71M
Total Long-Term Assets	$44.97M	$46.25M
Total Assets	$56.49M	$59.96M
YoY Change	-5.8%	49.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$299.0K	$1.013M
YoY Change	-70.48%	316.87%
Accrued Expenses	$2.505M	$2.843M
YoY Change	-11.89%	127.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$875.0K	$375.0K
YoY Change	133.33%	-83.7%
Total Short-Term Liabilities	$14.44M	$15.01M
YoY Change	-3.81%	64.23%
LONG-TERM LIABILITIES
Long-Term Debt	$8.742M	$9.549M
YoY Change	-8.45%
Other Long-Term Liabilities	$143.0K	$3.965M
YoY Change	-96.39%	1045.95%
Total Long-Term Liabilities	$8.989M	$13.51M
YoY Change	-33.48%	3805.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.44M	$15.01M
Total Long-Term Liabilities	$8.989M	$13.51M
Total Liabilities	$23.42M	$28.52M
YoY Change	-17.87%	200.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$99.90M
YoY Change
Common Stock	$133.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.06M	$31.44M
YoY Change
Total Liabilities & Shareholders Equity	$56.49M	$59.96M
YoY Change	-5.8%	49.75%

Cashflow Statement

Concept	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.901M	-$2.787M
YoY Change	4.09%	30.11%
Depreciation, Depletion And Amortization	$1.059M	$971.0K
YoY Change	9.06%	51.25%
Cash From Operating Activities	$126.0K	-$1.270M
YoY Change	-109.92%	-1648.78%
INVESTING ACTIVITIES
Capital Expenditures	$29.00K	-$519.0K
YoY Change	-105.59%	37.3%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$433.0K	-$519.0K
YoY Change	-16.57%	37.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net	$125.0K
YoY Change
Cash From Financing Activities	-$304.0K	-141.0K
YoY Change	115.6%	-100.96%
NET CHANGE
Cash From Operating Activities	$126.0K	-1.270M
Cash From Investing Activities	-$433.0K	-519.0K
Cash From Financing Activities	-$304.0K	-141.0K
Net Change In Cash	-$611.0K	-1.930M
YoY Change	-68.34%	-113.48%
FREE CASH FLOW
Cash From Operating Activities	$126.0K	-$1.270M
Capital Expenditures	$29.00K	-$519.0K
Free Cash Flow	$97.00K	-$751.0K
YoY Change	-112.92%	-263.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	STRM	Effect Of Dilutive Securities Stock Options Restricted Stocks EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks		shares
CY2022Q2	STRM	Effect Of Dilutive Securities Stock Options Restricted Stocks EffectOfDilutiveSecuritiesStockOptionsRestrictedStocks		shares
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease		usd
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001008586
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2022Q2	STRM	Provision For Deferred Income Taxes ProvisionForDeferredIncomeTaxes		usd
CY2023Q2	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses		usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-04-30
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	000-28132
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	STREAMLINE HEALTH SOLUTIONS, INC.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-1455414
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	2400 Old Milton Pkwy.
CY2023Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Box 1353
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Alpharetta
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30009
CY2023Q2	dei	City Area Code CityAreaCode	(888)
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	997-8732
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2023Q2	dei	Trading Symbol TradingSymbol	STRM
CY2023Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58641313	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5987000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6598000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	94000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	132000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4280000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7719000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	535000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	960000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	710000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11519000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	15987000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	255000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	246000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	99000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	79000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32000	usd
CY2023Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	6659000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	6224000	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	5838000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	5846000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3077000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2627000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14343000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14793000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	23089000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	23089000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1598000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1695000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	44967000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	45534000	usd
CY2023Q2	us-gaap	Assets Assets	56486000	usd
CY2023Q1	us-gaap	Assets Assets	61521000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	299000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	626000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2505000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3265000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	875000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	750000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7382000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8361000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	3374000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	3738000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14435000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16775000	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	8742000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	8964000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	104000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	167000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	143000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	104000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8989000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9235000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	23424000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26010000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58636411	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58636411	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57567210	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57567210	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	586000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	576000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132379000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	131973000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99903000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97038000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	33062000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56486000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61521000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5332000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5935000	usd
CY2023Q2	STRM	Cost Of Software As Service CostOfSoftwareAsService	1589000	usd
CY2022Q2	STRM	Cost Of Software As Service CostOfSoftwareAsService	1497000	usd
CY2023Q2	STRM	Cost Of Maintenance And Support CostOfMaintenanceAndSupport	89000	usd
CY2022Q2	STRM	Cost Of Maintenance And Support CostOfMaintenanceAndSupport	46000	usd
CY2023Q2	STRM	Cost Of Professional Fees And Licenses CostOfProfessionalFeesAndLicenses	1108000	usd
CY2022Q2	STRM	Cost Of Professional Fees And Licenses CostOfProfessionalFeesAndLicenses	1666000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3806000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4501000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1701000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1312000	usd
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	35000	usd
CY2022Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	90000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	8328000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	9112000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2996000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3177000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	248000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	132000	usd
CY2023Q2	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	364000	usd
CY2022Q2	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	500000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2848000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2776000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2787000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55970880	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47028463	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35511000	usd
CY2023Q2	STRM	Surrender Of Shares During Period Value SurrenderOfSharesDuringPeriodValue	-179000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	595000	usd
CY2023Q2	STRM	Adoption Of Asu AdoptionOfASU	36000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	33062000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	34044000	usd
CY2022Q2	STRM	Surrender Of Shares During Period Value SurrenderOfSharesDuringPeriodValue	-141000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2787000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	31442000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2787000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1059000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1103000	usd
CY2023Q2	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	364000	usd
CY2022Q2	STRM	Acquisition Earnout Valuation Adjustments AcquisitionEarnoutValuationAdjustments	500000	usd
CY2023Q2	STRM	Provision For Deferred Income Taxes ProvisionForDeferredIncomeTaxes	39000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	572000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	326000	usd
CY2022Q2	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	13000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-3900000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	678000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-8000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-327000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	235000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-795000	usd
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	739000	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1042000	usd
CY2022Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	271000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	126000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1270000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2023Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	404000	usd
CY2022Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	519000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-433000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-519000	usd
CY2023Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	125000	usd
CY2023Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	179000	usd
CY2022Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	141000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-304000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-141000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-611000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1930000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6598000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9885000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5987000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7955000	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zz0pnvQOvrL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrsXjihe69je">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>
CY2023Q1	STRM	Acquisition Earnout Liability Fair Value AcquisitionEarnoutLiabilityFairValue	3738000	usd
CY2023Q2	STRM	Acquisition Earnout Liability Fair Value AcquisitionEarnoutLiabilityFairValue	3374000	usd
CY2023Q2	STRM	Acquisition Earnout Liability Change In Valuation AcquisitionEarnoutLiabilityChangeInValuation	364000	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.015	pure
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5332000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5935000	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	3161000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	27668000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	the Company expects to recognize approximately 68% over the next 12 months and the remainder thereafter
CY2023Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	94000	usd
CY2023Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	94000	usd
CY2023Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	194000	usd
CY2023Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	176000	usd
CY2023Q2	STRM	Deferred Costs Amortization Expenses DeferredCostsAmortizationExpenses	18000	usd
CY2022Q2	STRM	Deferred Costs Amortization Expenses DeferredCostsAmortizationExpenses	19000	usd
CY2023Q2	STRM	Deferred Commission Costs Accumulated Amortization DeferredCommissionCostsAccumulatedAmortization	949000	usd
CY2023Q1	STRM	Deferred Commission Costs Accumulated Amortization DeferredCommissionCostsAccumulatedAmortization	820000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2901000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2787000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55970880	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47028463	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55970880	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47028463	shares
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	35000	usd
CY2022Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	90000	usd
CY2023Q2	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	23000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	96000	usd
CY2023Q2	STRM	Adoption Of Asu AdoptionOfASU	36000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	132000	usd
CY2023Q2	STRM	Adoption Of Asu AdoptionOfASU	36000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	96000	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	32000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	32000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	48000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9625000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q2	STRM	Financing Cost Payable FinancingCostPayable	88000	usd
CY2023Q1	STRM	Financing Cost Payable FinancingCostPayable	69000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	96000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	105000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	9617000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	9714000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	875000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	750000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8742000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8964000	usd
CY2023Q2	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	53000	usd
CY2023Q2	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	11000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.02	pure
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	49884000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	333000	usd
CY2023Q2	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2019. All material state and local income tax matters have been concluded for years through January 31, 2018. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2019; however, carryforward losses that were generated prior to the tax year ended January 31, 2019 may still be adjusted by the IRS if they are used in a future period
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85000000	shares
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	6000	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	19000	usd

Files In Submission

Name	View Source	Status
0001493152-23-021263-index-headers.html	Edgar Link	pending
0001493152-23-021263-index.html	Edgar Link	pending
0001493152-23-021263.txt	Edgar Link	pending
0001493152-23-021263-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
strm-20230430.xsd	Edgar Link	pending
strm-20230430_def.xml	Edgar Link	unprocessable
strm-20230430_cal.xml	Edgar Link	unprocessable
strm-20230430_pre.xml	Edgar Link	unprocessable
strm-20230430_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2023 Q2 Form 10-Q Financial Statement

#000149315223021263 Filed on June 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM STREAMLINE HEALTH SOLUTIONS INC. Stock $strm

2023 Q2 Form 10-Q Financial Statement

#000149315223021263 Filed on June 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRM
STREAMLINE HEALTH SOLUTIONS INC. Stock $strm